3-methyl-but-2-enoic acid 4-bromo-phenyl ester | 112090-04-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 3-methyl-but-2-enoic acid 4-bromo-phenyl ester
• 英文别名: 3-methyl-but-2-enoic acid 4-bromophenyl ester；3-methylbut-2-enoic acid 4-bromophenyl ester；(4-bromophenyl) 3,3-dimethylacrylate；3-Methyl-buten-(2)-saeure-<4-brom-phenylester>；3-Methyl-buten-(2)-saeure-(4-brom-phenylester)；(4-bromophenyl) 3-methylbut-2-enoate
• CAS: 112090-04-7
• 化学式: C₁₁H₁₁BrO₂
• 分子量: 255.111
• InChiKey: RDOXILXISZRPFQ-UHFFFAOYSA-N

物化性质

• 熔点：
  25-26 °C
• 沸点：
  123-127 °C(Press: 1 Torr)
• 密度：
  1.370±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methyl-but-2-enoic acid 4-bromo-phenyl ester 在 aluminum (III) chloride 作用下， 生成 7-溴-2,2-二甲基苯并二氢吡喃-4-酮
  参考文献：
  名称：

  Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors

  摘要：

  式中变量的定义如规范中所述，对于预防或治疗哺乳动物的肺气肿和相关肺部疾病以及其他对RARγ激动剂类维生素A酸类药物敏感的疾病和病况是有用的，例如皮肤相关疾病，包括但不限于痤疮和牛皮癣。

  公开号：

  US20050148590A1
• 作为产物：
  描述：

  3-甲基巴豆酰氯 、 4-溴苯酚 在 sodium hydride 作用下， 生成 3-methyl-but-2-enoic acid 4-bromo-phenyl ester
  参考文献：
  名称：

  Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors

  摘要：

  式中变量的定义如规范中所述，对于预防或治疗哺乳动物的肺气肿和相关肺部疾病以及其他对RARγ激动剂类维生素A酸类药物敏感的疾病和病况是有用的，例如皮肤相关疾病，包括但不限于痤疮和牛皮癣。

  公开号：

  US20050148590A1

文献信息

• Acetylenes disubstituted with a phenyl or heteroaryl group and a
  申请人：Allergan, Inc.

  公开号：US05399561A1

  公开（公告）日：1995-03-21

  Compounds of the formula ##STR1## where R.sub.1 and R.sub.2 are hydrogen, lower alkyl of 1-6 carbons, or halogen; R.sub.3 is hydrogen, lower alkyl of 1-6 carbons, halogen, OR.sub.11, SR.sub.11, OCOR.sub.11, SCOR.sub.11, NH.sub.2, NHR.sub.11, N(R.sub.11).sub.2, NHCOR.sub.11 or NR.sub.11 COR.sub.11 ; X is O, S or NR' where R' is hydrogen or lower alkyl of 1-6 carbons; Y is phenyl or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl and oxazolyl; A is (CH.sub.2).sub.n where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.11, CH.sub.2 OCOR.sub.11, CHO, CH(OR.sub.12).sub.2, CHOR.sub.13 O, --COR.sub.7, CR.sub.7 (OR.sub. 12).sub.2, or CR.sub.7 OR.sub.13 O, where R.sub.7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R.sub.8 is an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R.sub.8 is phenyl or lower alkylphenyl, R.sub.9 and R.sub.10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower alkylphenyl, R.sub.11 is lower alkyl, phenyl or lower alkylphenyl, R.sub.12 is lower alkyl, and R.sub.13 is divalent alkyl radical of 2-5 carbons, have retinoid-like biological activity.

  式为##STR1##的化合物，其中R.sub.1和R.sub.2为氢、1-6碳的低烷基或卤素；R.sub.3为氢、1-6碳的低烷基、卤素、OR.sub.11、SR.sub.11、OCOR.sub.11、SCOR.sub.11、NH.sub.2、NHR.sub.11、N(R.sub.11).sub.2、NHCOR.sub.11或NR.sub.11 COR.sub.11；X为O、S或NR'，其中R'为氢或1-6碳的低烷基；Y为苯基或从吡啶基、噻吩基、呋喃基、吡啶嗪基、嘧啶基、吡嗪基、噻唑基和噁唑基组成的杂环基；A为(CH.sub.2).sub.n，其中n为0-5，具有3-6碳的低支链烷基、具有3-6碳的环烷基、具有2-6碳和1或2个双键的烯基、具有2-6碳和1或2个三键的炔基；B为氢、COOH或其药用可接受盐，COOR.sub.8、CONR.sub.9 R.sub.10、--CH.sub.2 OH、CH.sub.2 OR.sub.11、CH.sub.2 OCOR.sub.11、CHO、CH(OR.sub.12).sub.2、CHOR.sub.13 O、--COR.sub.7、CR.sub.7 (OR.sub. 12).sub.2或CR.sub.7 OR.sub.13 O，其中R.sub.7为含有1至5个碳的烷基、环烷基或烯基，R.sub.8为1至10个碳的烷基或5至10个碳的环烷基，或R.sub.8为苯基或低烷基苯基，R.sub.9和R.sub.10独立地为氢、1至10个碳的烷基或5-10个碳的环烷基，或苯基或低烷基苯基，R.sub.11为低烷基、苯基或低烷基苯基，R.sub.12为低烷基，R.sub.13为2-5碳的二价烷基基团，具有类似视黄醇的生物活性。
• Compounds having activity as inhibitors of cytochrome P450RAI
  申请人：Allergan Sales, Inc.

  公开号：US06359135B1

  公开（公告）日：2002-03-19

  Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

  具有通式1的化合物，其中符号的含义在说明书中定义，是细胞色素P450RAI（视黄酸诱导型）酶的抑制剂，并用于治疗对视黄酸治疗有反应的疾病。
• Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
  申请人：Allergan Sales, Inc.

  公开号：US06313107B1

  公开（公告）日：2001-11-06

  Novel compounds having the Formulas 1 through 8, wherein the symbols have the meaning defined in the specification, and certain previously known compounds have been discovered to act as inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids. The compound can also be used in co-treatment with retinoids.

  具有1至8号式的新化合物，其中符号的含义在说明书中有定义，并且已发现某些先前已知的化合物可作为细胞色素P450RAI（诱导性维生素A酸）酶的抑制剂，并用于治疗对维生素A酸治疗产生响应的疾病。该化合物还可与维生素A酸一起进行联合治疗。
• 1-imidazolyl substituted tetrahydronaphthalene derivatives as inhibitors of eytochrome P450RAI
  申请人：Allergan, Inc.

  公开号：US06603019B2

  公开（公告）日：2003-08-05

  Compounds having Formula 4 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids

  具有公式4的化合物，其中符号的含义在规范中定义，是细胞色素P450RAI（诱导维甲酸）酶的抑制剂，并用于治疗对维甲酸类药物治疗有反应的疾病。
• Methods for identifying inhibitors of cytochrome P450RAI
  申请人：Vasudevan Jayasree

  公开号：US06855512B2

  公开（公告）日：2005-02-15

  A method of identifying a compound which is an inhibitor of the enzyme cytochrome P450RAI is performed by selecting a compound that has retinoid activity in an art recognized assay and includes a benzoic acid, benzoic acid ester, naphthoic acid ester or heteroaryl carboxylic acid or ester moiety, with a partial structure of —A(R 2 )—(CH 2 ) n—COOR 8 where n is 0 and the remaining variables are as described in the specification and claims. Thereafter, a compound having the cytochrome P450RAI inhibitory activity is identified and selected where the compound has the —A(R 2 )—(CH 2 ) 2 —COOR 8 partial structure wherein the variable n is 1 or 2.

  一种识别抑制酶细胞色素P450RAI的化合物的方法，包括选择在公认的试验中具有视黄醇活性的化合物，并包括苯甲酸、苯甲酸酯、萘甲酸酯或杂环羧酸或酯基团，具有部分结构- A（R2）-（CH2）n-COOR8，其中n为0，其余变量如说明书和权利要求所述。然后，识别并选择具有细胞色素P450RAI抑制活性的化合物，其中化合物具有- A（R2）-（CH2）2-COOR8部分结构，其中变量n为1或2。